FDA Faulted for Inappropriate Collaboration With Drug Company Before Approving Alzheimer’s Drug
• After major pushback, the FDA approved Biogen’s $56,000 drug, Aduhelm, in 2021. • The 18-month investigation found that the FDA and Biogen had an “atypical” number of meetings. “The committee also f
Original source: https://rumble.com/v2470mk-fda-faulted-for-inappropriate-collaboration-with-drug-company-before-approv.html
